Dyal Co., a small M&A boutique, landed a lead role on the the $8.7 billion Novartis-AveXis deal. The firm has roughly 15 employees and is led by ex-Goldman Sachs rainmaker Gordon Dyal. Dyal was the former co-chairman of investment banking at Goldman, where he spent years leading M&A…
News
- A small boutique landed a lucrative lead role on the $8.7 billion Novartis-AveXis deal
- Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we ...
Novartis isn't the only big pharma/biotech to be interested in gene and cell therapies. In January, Celgene made a $9 billion bet on Juno Therapeutics, a cancer drugmaker that's working on cell therapies. The deal also drummed up excitement for a possible deal for Bluebird Bio, another company…
- Frontier Airlines launching new SA flights to several destinations
“Raleigh-Durham is an especially important area for research and development,” said Maria Zannes, president and CEO of San Antonio-based bioAffinity Technologies. “North Carolina's universities and medical centers most certainly can be important partners for San Antonio's biotech sector.”.
- Collaborate with institute advisers for academic support, says team lead
Maria Rogers, Health and Biosciences Institute advising team lead, has been the team lead adviser for a year at this college, but was a senior ... Students wanting to transfer to Texas A&M University-San Antonio or the University of Texas at San Antonio can speak with a university adviser in…
- Cerebral Magnetics $1.00 million Financing. Peter T Fox Filed Apr 6 form D
The filler's business is Biotechnology. The form D was signed by Peter T Fox CEO. The company was incorporated more than five years ago. The filler's address is: 6850 Rock Road, San Antonio, Tx, Texas, 78229. Peter Thornton Fox is the related person in the form and it has address: 6850 Rock Road…